Cipla Limited
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- India
- Registered address
- Plot No. A-2, A-33, A-42 and A-37/2/2, Patalganga Industrial Area, Raigad, Maharashtra 410220, India (IND)
- Operations here
- analysisapi manufacturelabelmanufacturepack
- FDA identifiers
- FEI 3002806710 · DUNS 916940208
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- VAIDrug Quality Assurance2024-04-04
- VAIDrug Quality Assurance2019-11-13
- VAIDrug Quality Assurance2017-12-06
- VAIDrug Quality Assurance2015-10-16
- NAIDrug Quality Assurance2015-02-27
- NAIDrug Quality Assurance2012-06-06
- VAIDrug Quality Assurance2009-02-06
Drugs this plant is listed as making
12 distinct drugs across 20 products name this site in their FDA label.
- AbacavirCipla USA Inc.
- Abacavir and lamivudineCipla USA Inc.
- albuterol sulfateExelan Pharmaceuticals, Inc.
- AmbrisentanCipla USA Inc.
- Amlodipine BesylateCipla USA Inc.
- CinacalcetCipla USA Inc.
- Darifenacin HydrobromideCipla USA Inc.
- darunavirCipla USA Inc.
- efavirenz, emtricitabine and tenofovir disoproxil fumarateCipla USA Inc.
- Emtricitabine And Tenofovir Disoproxil FumarateCipla USA Inc.
- EscitalopramCipla USA Inc.
- ritonavir 100 mgCipla USA Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.